the quick response is PADR/PADER Patient Adverse Drug Event Reporting .
Basically, when a new product hits the market, there's s process called Pharmacovigilance that tracks adverse drug events like PIP, so pharmaceutical manufacturers can improve their product based on user reactions. Preservatives and carrier agents are typically more responsible for adverse effects than 'active ingredients'. There's a percentage of failure built-in for all products because human error plays a role in the manufacturing process.
but...back to PIP...if enough people report it, then the company has to take action to rectify the PIP problem. If the problem is not resolved within a certain number of days then an audit of the process is done. There are scheduled audits and 'surprise' audits. If a company fails like 3 schedule audits, or say 1 scheduled and 1 surprise audit they are given X number of days to comply with FDA standards, or face fines and then have their product removed from FDA approval. The european system is considerably more stringent than the north american system, and compounds such as parabolan or omnadren or deca feel different than the american version because the preservatives, fillers and carriers have been more scrutinized and refined than those used in the north american system. i won't bore you with all the details, but for those who think that one oil is good for all powders...well, the European model shows that some powders bond better with different oils to keep the preservative levels low (all in controlled pharma labs) Try batching Test Prop in Olive Oil at low bb and lower ba concentrations, and try the same ratio for sesame oil and the same for cottonseed and the same for grapeseed, and you'll notice differences not only in PIP but also in dispersion rates, how less likely crash is for some oils, and even how high/low of a temp you can go to control the level of oxidation of the actual compound.
this was my job for over two years years...working to make sure that deca, primo, sustanon, proviron, and a host of other products were being made according to standard for a pharmaceutical company, and then supporting the upsell of these products into markets where other companies were already providing established goods.
